These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32720048)

  • 1. Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
    Murphy BL; Yi M; Arun BK; Gutierrez Barrera AM; Bedrosian I
    Ann Surg Oncol; 2020 Nov; 27(12):4613-4621. PubMed ID: 32720048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
    Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
    Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer.
    Basu NN; Hodson J; Chatterjee S; Gandhi A; Wisely J; Harvey J; Highton L; Murphy J; Barnes N; Johnson R; Barr L; Kirwan CC; Howell S; Baildam AD; Howell A; Evans DG
    Sci Rep; 2021 Feb; 11(1):2847. PubMed ID: 33531640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-reducing mastectomy for the prevention of primary breast cancer.
    Carbine NE; Lostumbo L; Wallace J; Ko H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD002748. PubMed ID: 29620792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
    Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
    Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.
    Mai PL; Lagos VI; Palomares MR; Weitzel JN
    Ann Surg Oncol; 2008 Dec; 15(12):3415-21. PubMed ID: 18836779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    Yoshimura A; Okumura S; Sawaki M; Hattori M; Ishiguro J; Adachi Y; Kotani H; Gondo N; Kataoka A; Iwase M; Onishi S; Sugino K; Terada M; Horisawa N; Mori M; Takaiso N; Hyodo I; Iwata H
    Breast Cancer; 2018 Sep; 25(5):539-546. PubMed ID: 29520501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.
    Heemskerk-Gerritsen BA; Rookus MA; Aalfs CM; Ausems MG; Collée JM; Jansen L; Kets CM; Keymeulen KB; Koppert LB; Meijers-Heijboer HE; Mooij TM; Tollenaar RA; Vasen HF; ; Hooning MJ; Seynaeve C
    Int J Cancer; 2015 Feb; 136(3):668-77. PubMed ID: 24947112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Management of Patients at Risk for Hereditary Breast Cancer with Variants of Uncertain Significance in the Era of Multigene Panel Testing.
    Chang J; Seng S; Yoo J; Equivel P; Lum SS
    Ann Surg Oncol; 2019 Oct; 26(10):3389-3396. PubMed ID: 31342386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
    Evans DG; Ingham SL; Baildam A; Ross GL; Lalloo F; Buchan I; Howell A
    Breast Cancer Res Treat; 2013 Jul; 140(1):135-42. PubMed ID: 23784379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of germline test results on surgical decision making in women with invasive breast cancer.
    Vargason AB; Turner CE; Shriver CD; Ellsworth RE
    Cancer Genet; 2022 Aug; 266-267():81-85. PubMed ID: 35868102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
    Jakub JW; Peled AW; Gray RJ; Greenup RA; Kiluk JV; Sacchini V; McLaughlin SA; Tchou JC; Vierkant RA; Degnim AC; Willey S
    JAMA Surg; 2018 Feb; 153(2):123-129. PubMed ID: 28903167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the effect of the American Society of Breast Surgery guidelines on contralateral prophylactic mastectomy rates for unilateral breast cancer.
    Steadman JA; Hoskin TL; Klassen C; Boughey JC; Degnim AC; Piltin MA; Mrdutt MM; Johnson JE; Hieken TJ
    Surgery; 2024 Mar; 175(3):677-686. PubMed ID: 37863697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.
    Ro V; McGuinness JE; Guo B; Trivedi MS; Jones T; Chung WK; Rao R; Levinson E; Koval C; Russo D; Chilton I; Kukafka R; Crew KD
    JCO Oncol Pract; 2022 Apr; 18(4):e472-e483. PubMed ID: 34705516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.
    Jia Z; Li J; Zhang Y; Wang X; Xing J; Xing Z; Huang X; Liu G; Zhang M; Feng K; Wu J; Wang W; Wang J; Liu J; Wang X
    Cancer Cell Int; 2021 Sep; 21(1):512. PubMed ID: 34563200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk management decisions in women with BRCA1 and BRCA2 mutations.
    Morgan R; Brown A; Hamman KJ; Sampson J; Naik A; Massimino K
    Am J Surg; 2018 May; 215(5):899-903. PubMed ID: 29499861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
    Chiba A; Hoskin TL; Hallberg EJ; Cogswell JA; Heins CN; Couch FJ; Boughey JC
    Ann Surg Oncol; 2016 Oct; 23(10):3232-8. PubMed ID: 27338744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.